Norway Microbiome Therapeutics Market Size & Outlook
The microbiome therapeutics market in Norway is expected to reach a projected revenue of US$ 4.4 million by 2030. A compound annual growth rate of 36% is expected of Norway microbiome therapeutics market from 2023 to 2030.
- Pharmaceuticals
- Metabolic Disorders Treatment
- Microbiome Therapeutics Market Outlook
- Metabolic Disorders Treatment
Revenue, 2022 (US$M)
$0.4
Forecast, 2030 (US$M)
$4.4
CAGR, 2023 - 2030
36.0%
Report Coverage
Norway
Norway Microbiome Therapeutics Market, 2018-2030 (US$M)
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the microbiome therapeutics market
Every figure cited from GVR research
Norway microbiome therapeutics market highlights
- The Norway microbiome therapeutics market generated a revenue of USD 0.4 million in 2022 and is expected to reach USD 4.4 million by 2030.
- The Norway market is expected to grow at a CAGR of 36% from 2023 to 2030.
- In terms of segment, c. difficile was the largest revenue generating application in 2022.
- C. difficile is the most lucrative application segment registering the fastest growth during the forecast period.
Microbiome therapeutics market data book summary
| Market revenue in 2022 | USD 0.4 million |
| Market revenue in 2030 | USD 4.4 million |
| Growth rate | 36% (CAGR from 2022 to 2030) |
| Largest segment | C. difficile |
| Fastest growing segment | C. difficile |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C. difficile, Crohns disease, Inflammatory Bowel Disease, Diabetes |
| Key market players worldwide | Finch Therapeutics Group Inc, Vedanta |
Other key industry trends
- In terms of revenue, Norway accounted for 0.4% of the global microbiome therapeutics market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany microbiome therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 25.1 million by 2030.
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Microbiome Therapeutics Market Scope
Microbiome Therapeutics Market segmentation & scope
Microbiome Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Vedanta | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | www.vedantalimited.com/ |
| Finch Therapeutics Group Inc | View profile | 1 | 75 State Street, Suite 100, Boston, MA, United States, 02109 | www.finchtherapeutics.com |
| 4D Pharma | View profile | 101-250 | Aberdeen, Aberdeen City, United Kingdom, Europe | www.4dpharmaplc.com |
| Seres Therapeutics Inc | View profile | 233 | 101 Cambridgepark Drive, Cambridge, MA, United States, 02140 | www.serestherapeutics.com |
| Locus Biosciences | View profile | 51-100 | Morrisville, North Carolina, United States, North America | www.locus-bio.com/ |
| ENTEROME | View profile | 51-100 | Paris, Ile-de-France, France, Europe | www.enterome.com |
| Intralytix | View profile | 11-50 | Baltimore, Maryland, United States, North America | www.intralytix.com/ |
| Microbiotica | View profile | 11-50 | Cambridge, Cambridgeshire, United Kingdom, Europe | www.microbiotica.com/ |
| Second Genome | View profile | 11-50 | San Francisco, California, United States, North America | www.secondgenome.com |
| Vedanta Biosciences | View profile | 101-250 | Cambridge, Massachusetts, United States, North America | www.vedantabio.com |
Norway Microbiome Therapeutics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Microbiome Therapeutics Market Outlook will help companies and investors design strategic landscapes.
C. Difficile was the largest segment with a revenue share of 75.0% in 2022.
Horizon Databook has segmented the Norway microbiome therapeutics market based on c. difficile, crohns disease, inflammatory bowel disease, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
- Norway Microbiome Therapeutics Market Application Outlook (Revenue, USD Million , 2018-2030)
- Crohns disease
- C. difficile
- Inflammatory Bowel Disease
- Others
- Diabetes
- Norway Microbiome Therapeutics Market Type Outlook (Revenue, USD Million , 2018-2030)
- Microbiome Drugs
- FMT
Reasons to subscribe to Microbiome Therapeutics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Microbiome Therapeutics Market Outlook databook
- Our clientele includes a mix of Microbiome Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway Microbiome Therapeutics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Norway Microbiome Therapeutics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Norway Microbiome Therapeutics Market, 2018-2030 (US$M)
Norway microbiome therapeutics market statistics, by application, 2018-2030 (US$M)
